- Bupa Platinum consultant
- Fee assured
- Awaiting verification
- Open Referral network
- Video and telephone consultations
- Home chemotherapy
I am a Consultant Medical Oncologist at the Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust, Cancer Centre. I have been in post here since 2020. I am a Visiting Lecturer at the University of Portsmouth.
Prior to 2020, I was a Consultant Medical Oncologist at York Teaching Hospital NHS Foundation Trust and Harrogate and District Hospital NHS Foundation Trust. I also held the post of Clinical Lecturer at the Hull & York Medical School.
I was born and grew up in the UK. After completing medical training at St. Bartholomewâ€™s Hospital Medical College, I worked in hospitals in Kent, Essex and London. I completed Medical Oncology training in London and the South East, at The Royal Marsden Hospital, Guys and St Thomasâ€™ and The Kent Oncology Centre.
My BSc is in Human Genetics at UCL. I spent 3 years at The University of Kent lecturing and carrying out cancer research in the field of growth factor receptors. Currently, I am research active and involved with collaborative clinical trials.
My spare time is spent with my family and climbing and swimming to keep fit; I also enjoy reading and guitar.
I specialise in the management and treatment of Thoracic Cancers and Cancers of the Upper GI Tract including HPB.
These cancer sites include: Lung Cancer, Mesothelioma, Thymoma, Cancer of the Oesophagus, Stomach, Pancreas, Bile ducts, Small Intestine and Liver. I also treat NETs (Neuroendocrine Tumours) and have an interest in the treatment of Colorectal Cancer and Cancer of Unknown Origin.
I believe passionately in providing personalised and holistic cancer care, respectful of patientsâ€™ wishes and their dignity. Excellent communication with patients and their loved ones, professionalism, kindness, respect and compassion is at the heart of everything I do.
Areas of interest
Bile Duct Cancer;
Small Intestine Cancer;
Cancer of Unknown Origin
Current NHS consultant posts held
Consultant Medical Oncologist at Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust. Hampshire, UK
Upper GI and HPB Cancers
EGFR Tumour Biology and Therapeutics
2009: â€œTop 10 Citedâ€ award for published paper in European Journal Of Cancer
2007: Prize for best research poster presentation: EGFR Cancer Therapeutics, at Annual Research Meeting, MTW Trust 2007
1996: Distinction Award in Medicine and Surgery
(Additional) Languages spoken
- Cantonese - Basic
2022: Banna GL, Chan S, et. al. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. Eur J Cancer. 2022 May;166:287-299
2021: Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM) Lancet Oncol. 2021 Nov;22(11):1530-1540.
2021: Lester J, Escriu C, Khan S, Hudson E, Mansy T, Conn A, Chan S, Powell C, Brock J, Conibear J, Nelless L, Nayar V, Zhuo X, Durand A, Amin A, Martin P, Zhang X, Pawar V. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. BMC Cancer. 2021 May 7;21(1):515.
2020: Radical Chemoradiation and adjuvant Durvalumab for Stage III Non Small Cell Lung Cancer â€“ Real World Experience, St James University Hospital, Leeds, UK. S Chan et. al . Poster Presentation and abstract BTOG 2020
2018: Colorectal Cancer Presenting as Single Pulmonary Hilar Lymph Node Metastasis; Ahmed M. Habib,Xenophon Kassianides, Samuel Chan, Mahmoud Loubani, and Syed Qadri. Case Reports in Surgery
Volume 2018 (2018)
2017: Safety Aspects of Immunotherapy. Poster Presentation at York Teaching Hospital NHS Foundation Trust Patient Safety Conference.
2015: Safety Mechanisms for a Clinical Chemotherapy Service. Poster Presentation at York Teaching Hospital NHS Foundation Trust Inaugural Patient Safety Conference. 22nd May 2015, York
2014: Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. Khan F, Ottensmeier C, Popat S, Dua D, Dorey N, Ellis S, Upadhyay S, Califano R, Chan S, Lee L, Ali CW, Nicolson M, Bates AT. Eur J Cancer. 2014 Jul;50(10):1717-21.
2012: A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines. Blackburn E, Zona S, Murphy ML, Brown IR, Chan SK, Gullick WJ. Breast Cancer Res Treat. 2012 Jul;134(1):53-9.
For a more comprehensive list of publications; please contact me directly.
Courses offered to GPs
I have held teaching seminars for GPs and allied health professionals previously in the fields of Lung Cancer and Bowel Cancer.
I have previously been a speaker at regional meetings for Mesothelioma UK, Roy Castle Lung Cancer Foundation and various academic institutions and pharmaceutical companies.
Please feel free to contact me for any further meetings - I would be very happy to provide.
- MBBS St Bartholomew's Hospital, London University 1998
- BSc Human Genetics University College London 1995
- MRCP MRCP (UK) 2001
- Medical Oncology CCT London and KSS Deanery (UK) 2010
Reference number 4547451
Professional bodies (positions held - last 3 yrs)
- Member RCP Royal College of Physicians (UK) 2018
- Member ACP Association Cancer Physicians 2018
- Member MPS Medical Protection Society 2018
- Visiting Lecturer University of Portsmouth 2021
- Consultant Advisor Roy Castle Lung Cancer Foundation 2018
- MDT member Wessex NET MDT 2021
Details of entry to specialist register
- Medical Oncology, Oncology; GMC registered , 2010
Affiliations / memberships
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Emergency Helpline number for Healthcare At Home Team (if on Chemotherapy): number supplied by Healthcare at Home Team on an individual basis.
Emergency Contact No.for Dr S Chan:
0753 4030 835
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (1-5)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (1-5)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (1-5)
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-56 days - (1-5)
Queen Alexandra Hospital (1-5)